Arrowhead Pharmaceuticals: Study Success in Severe Hypertriglyceridemia Triggers Nearly 20% Stock Surge!

Plozasiran lowers triglycerides by up to 81% in phase 3 studies and reduces acute pancreatitis events. The company plans to submit an expanded application for approval in the USA based on the data within this year. The stock price has seen a dynamic increase towards the 52-week high due to the positive study results. Successful Efficacy Evidence in Phase 3 Studies Arrowhead Pharmaceuticals (ARWR) (i.) presented topline results from the global phase 3 studies SHASTA-3 and SHASTA-4 on July 22. The RNAi drug Plozasiran was investigated in...